There are currently no generic versions of Victoza (liraglutide) available. The brand-name drug is protected by a patent that is set to expire in 2017. After this patent expires, several companies could manufacture a generic version, provided there are no outstanding circumstances (such as lawsuits) that extend the exclusivity period of this medication.
Victoza® (liraglutide) is a prescription diabetes medication that is taken as a once-daily injection. It belongs to a class of drugs known as incretin mimetics or glucagon-like peptide-1 (GLP-1) receptor agonists.
Victoza is made by Novo Nordisk. At this time, no generic versions are available.
The first patent for Victoza currently expires in August 2017. This is the earliest predictable date that a generic version of Victoza could become available. However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for specific Victoza uses.
Once the patent expires, several companies will likely begin manufacturing a generic Victoza drug.
No -- liraglutide is the active ingredient in Victoza, but is not a generic version of it. What can be confusing is that oftentimes, the active ingredient of any drug is referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.